Medtronic Raises 2027 Forecasts Amid Strong Heart Device Demand

Medtronic has increased its fiscal 2027 revenue growth outlook, driven by robust demand for its heart devices used in complex cardiovascular procedures. The company has also raised the lower end of its adjusted per share profit forecast to $5.94, up from $5.90, while maintaining the upper limit at $6. This adjustment reflects a projected annual organic revenue growth of 7.25% to 7.75%, an increase from the previous estimate of 6.75% to 7.25%.

Strategic Investments in Heart-Valve and Robotics

In line with its growth strategy, Medtronic has announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic is investing $700 million in Cornerstone Robotics, obtaining rights to distribute a robotic surgical device in select markets outside the U.S. This move aims to enhance Medtronic's offerings in the robotic surgery space, complementing its existing Hugo device.

CEO Geoff Martha highlighted the increasing adoption of new technologies and a steady rise in surgical demand as key factors behind the company's optimistic outlook. "The breadth of performance across our businesses and contributions from newer growth platforms provide us with confidence," Martha stated during a post-earnings call.

Cardiovascular Segment Sees Significant Growth

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, amounting to $3.93 billion. This growth was significantly driven by the company's pulsed field ablation portfolio, which treats irregular heart rhythms and experienced an 88% growth. Medtronic's adjusted quarterly per share profit reached $1.45 on revenue of $9.76 billion, surpassing analyst estimates of $1.39 per share on $9.55 billion in revenue, according to LSEG-compiled data.

Financially, Medtronic benefited from tariff refunds that nearly offset the duties paid during the quarter. However, the company has not factored future refunds into its financial projections. Thierry Pieton, Medtronic's finance chief, noted that while these refunds provided a temporary boost, they are not included in the future outlook.

Geoff Martha emphasized the company's focus on high-growth segments within medtech, targeting large patient pools and substantial market segments. "We've maintained a steady cadence of mergers and acquisitions, prioritizing areas we believe will become significant segments," Martha said, underscoring Medtronic's strategic direction.